J. N. Atkins

1.6k total citations
24 papers, 1.2k citations indexed

About

J. N. Atkins is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J. N. Atkins has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in J. N. Atkins's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). J. N. Atkins is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). J. N. Atkins collaborates with scholars based in United States, Canada and Ireland. J. N. Atkins's co-authors include Norman Wolmark, Bernard Fisher, Neil Abramson, Richard G. Margolese, Arthur P. DeCillis, N V Dimitrov, Birol Emir, James J. Dignam, D. L. Wickerham and L Deschênes and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The American Journal of Medicine.

In The Last Decade

J. N. Atkins

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. N. Atkins United States 13 754 643 270 256 174 24 1.2k
B van Ooijen Netherlands 18 528 0.7× 347 0.5× 243 0.9× 209 0.8× 326 1.9× 27 1.1k
Neal Osborn United States 12 680 0.9× 361 0.6× 560 2.1× 380 1.5× 267 1.5× 17 1.4k
Sharon Forsyth United Kingdom 10 639 0.8× 423 0.7× 316 1.2× 493 1.9× 242 1.4× 27 1.2k
Hadar Goldvaser Israel 15 450 0.6× 381 0.6× 103 0.4× 185 0.7× 83 0.5× 71 899
William D. George United Kingdom 7 329 0.4× 397 0.6× 250 0.9× 142 0.6× 132 0.8× 9 763
Enrique González‐Billalabeitia Spain 19 580 0.8× 399 0.6× 54 0.2× 365 1.4× 154 0.9× 75 1.3k
Jurjees Hasan United Kingdom 15 371 0.5× 185 0.3× 70 0.3× 197 0.8× 150 0.9× 53 919
Charles Kuzma United States 11 697 0.9× 518 0.8× 139 0.5× 261 1.0× 122 0.7× 20 1.3k
Hugh Bishop United Kingdom 6 524 0.7× 643 1.0× 259 1.0× 187 0.7× 171 1.0× 11 1.0k
A Boneu France 15 365 0.5× 103 0.2× 168 0.6× 138 0.5× 285 1.6× 30 1.2k

Countries citing papers authored by J. N. Atkins

Since Specialization
Citations

This map shows the geographic impact of J. N. Atkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. N. Atkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. N. Atkins more than expected).

Fields of papers citing papers by J. N. Atkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. N. Atkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. N. Atkins. The network helps show where J. N. Atkins may publish in the future.

Co-authorship network of co-authors of J. N. Atkins

This figure shows the co-authorship network connecting the top 25 collaborators of J. N. Atkins. A scholar is included among the top collaborators of J. N. Atkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. N. Atkins. J. N. Atkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Atkins, J. N., et al.. (2024). The Black in Marine Science Blueprint. Integrative and Comparative Biology. 64(4). 1055–1063.
2.
Vassilakopoulou, Maria, Minhee Won, W.J. Curran, et al.. (2015). BRCA1 Protein Expression Predicts Survival in Glioblastoma Multiforme (GBM) Patients From a RTOG Cohort. International Journal of Radiation Oncology*Biology*Physics. 93(3). S141–S141. 1 indexed citations
3.
Bear, Harry D., Gong Tang, Priya Rastogi, et al.. (2011). The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.. Journal of Clinical Oncology. 29(18_suppl). LBA1005–LBA1005. 33 indexed citations
4.
Siziopikou, Kalliopi P., Melody Cobleigh, Stewart Anderson, et al.. (2011). Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43.. Journal of Clinical Oncology. 29(15_suppl). 588–588. 1 indexed citations
5.
Wolmark, Norman, Greg Yothers, M J O'Connell, et al.. (2009). A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. Journal of Clinical Oncology. 27(18_suppl). LBA4–LBA4. 47 indexed citations
6.
Wolmark, Norman, Greg Yothers, M J O'Connell, et al.. (2009). A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. Journal of Clinical Oncology. 27(18S). LBA4–LBA4. 20 indexed citations
7.
Palesh, Oxana, Karen M. Mustian, Charles E. Heckler, et al.. (2009). A phase III randomized prospective trial of the effect of psychotherapy on distress in 287 prostate cancer patients: A URCC CCOP Study. Journal of Clinical Oncology. 27(15_suppl). 9637–9637. 1 indexed citations
8.
Rosenberg, Jonathan E., Susan Halabi, Ben L. Sanford, et al.. (2008). Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Annals of Oncology. 19(5). 946–950. 39 indexed citations
9.
Palesh, Oxana, Karen M. Mustian, Joseph A. Roscoe, et al.. (2008). Effect of paroxetine on depression and insomnia in 547 fatigued cancer patients undergoing 9501 chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 9501–9501. 3 indexed citations
10.
11.
Brahmer, Julie R., Ramaswamy Govindan, Silvia Novello, et al.. (2007). Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study. Journal of Clinical Oncology. 25(18_suppl). 7542–7542. 36 indexed citations
12.
Rocha‐Lima, Caio, James E. Herndon, J. N. Atkins, et al.. (2006). Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Annals of Oncology. 18(2). 331–337. 30 indexed citations
13.
Iqbal, Syma, Sarah Westcott McCoy, Heinz‐Josef Lenz, et al.. (2006). SWOG S0202: A phase II trial of gemcitabine and capecitabine in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinoma. Journal of Clinical Oncology. 24(18_suppl). 4134–4134. 3 indexed citations
14.
Kelly, Karen, Roy S. Herbst, John J. Crowley, et al.. (2006). Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342. Journal of Clinical Oncology. 24(18_suppl). 7015–7015. 20 indexed citations
15.
16.
Portenoy, Russell K., Montserrat Rué, Tito R. Mendoza, et al.. (2005). Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group. Annals of Oncology. 16(6). 972–980. 50 indexed citations
17.
Fisher, Bernard, James J. Dignam, Birol Emir, et al.. (1997). Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer. JNCI Journal of the National Cancer Institute. 89(22). 1673–1682. 366 indexed citations
18.
19.
Jackson, Don V., H. Bradley Wells, J. N. Atkins, et al.. (1988). Amelioration of vincristine neurotoxicity by glutamic acid. The American Journal of Medicine. 84(6). 1016–1022. 68 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B van Ooijen Breakdown of academic impact, for papers by Neal Osborn Breakdown of academic impact, for papers by Sharon Forsyth Breakdown of academic impact, for papers by Hadar Goldvaser Breakdown of academic impact, for papers by William D. George Breakdown of academic impact, for papers by Enrique González‐Billalabeitia Breakdown of academic impact, for papers by Jurjees Hasan Breakdown of academic impact, for papers by Charles Kuzma Breakdown of academic impact, for papers by Hugh Bishop Breakdown of academic impact, for papers by A Boneu
Rankless by CCL
2026